{'fraction_non_alphanumeric': 0.025487256371814093, 'fraction_numerical': 0.005247376311844078, 'mean_word_length': 5.418269230769231, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Acceptability of HIV vaccine trials in high‐risk heterosexual cohorts in Mombasa, Kenya

ObjectivesTo ascertain the level of acceptance of a prophylactic HIV vaccine trial in high-risk HIV-seronegative heterosexual cohorts of men, and women in Mombasa, Kenya, and to assess the anticipated effects of participation on risk behavior. MethodsStandardized questionnaire administered to a convenience sample of commercial sex workers, and trucking company employees enrolled in prospective cohort studies. ResultsNinety-six per cent of respondents believed that HIV was a major problem in Kenya, and 86% of men, and 94% of women perceived themselves at risk. One hundred per cent of women, and 84% of men expressed interest in participation in an HIV vaccine trial, after explanation of the experimental nature of the vaccine, double-blind placebo-controlled design, prolonged follow-up, and potential change in serostatus. Seventeen per cent of men, and 9% of women anticipated an increase in risk behavior as a result of participation. ConclusionThe majority of individuals in two high-risk cohorts were interested in participating in Phase III efficacy trials of HIV vaccines. A significant minority anticipated an increase in risk behavior, which emphasizes the need for intensive counseling, and education throughout a vaccine trial.